Context Therapeutics Appoints Dr. Karen Smith and Dr. Luke Walker to Board of Directors. Karen and Luke bring extensive operational, clinical, and transactional experience to support corporate and pipeline strategy. ir.contexttherapeutics.com/news-releases/… $CNTX, TCE, #CLDN6

Our CEO Martin Lehr will participate in a fireside chat with Emily Bodnar, PhD and host one-on-one meetings at the H.C. Wainwright & Co., LLC investor conference on Sept. 9th. $CNTX, #HCW2024

Claudin 6 (#CLDN6) programs from BioNTech SE and TORL Biotherapeutics, LLC demonstrate tumor responses across CLDN6-positive solid tumors in abstracts from #ESMO2024 Conference. Updated data to be presented on September 15th. $BNTX, $CNTX, #CART, #ADC

BioAtla and Context Therapeutics Announce Exclusive Worldwide License Agreement to Develop and Commercialize CT-202 (formerly BA3362), a Nectin-4 x CD3 T Cell Engaging Antibody. $CNTX, $BCAB

Context Therapeutics ($CNTX) announces poster presentation featuring CTIM-76, a CLDN6xCD3 T cell engager, at #SITC2024 on November 9th.

Context Therapeutics to Participate in UBS, Guggenheim, and Stifel Investor Conferences in November globenewswire.com/news-release/2…

Our CEO, Martin Lehr, will participate in a fireside chat at the 2024 UBS Healthcare Conference on November 13th at 2:45pm ET. Access the live webcast via: event.webcasts.com/starthere.jsp?…   #UBS, #Oncology

Our CEO, Martin Lehr, will present at the Stifel 2024 Healthcare Conference on November 19th at 1:50pm ET. Access the live webcast via: wsw.com/webcast/stifel…   #Stifel, #Oncology

Our CEO, Martin Lehr, will present at the Piper Sandler 36th Annual Healthcare Conference on December 4th at 11:00am ET.   #PiperSandler, #oncology, T cell engager

Context Therapeutics Appoints Andy Pasternak as Chairman of the Board of Directors. Andy is the former EVP, Chief Strategy Officer of Horizon Pharma (acquired for $28Bn) and Senior Partner at Bain & Company.

Join $CNTX at two premier events! Catch our presentation on Tuesday, April 8 at 10 AM ET during the Stifel Virtual Targeted Oncology Forum, and meet us at the 24th Annual Needham Virtual Healthcare Conference with 1x1 meetings on April 8th #Biotech

🚀Another big milestone for $CNTX: First patient dosed in Phase 1 clinical trial of CT-95, our mesothelin x CD3 T cell engaging bispecific antibody targeting solid tumors. CT-95 is Context’s second T cell engaging bispecific antibody to enter the clinic in 2025 💡 #Immunotherapy

📢 Context Therapeutics CEO Martin Lehr will join the T Cell Engagers panel at #AACR25! 🗓 Thursday, April 24 | 🕠 5:45–6:45 PM CT | 📍 Room W192 Moderated by Leerink Partners, the panel includes leaders from J&J, Zymeworks #Biotech #Immunotherapy #TCellEngagers

The Context team presented preclinical and translational data for CT-95, our mesothelin-targeting T cell engager, at #AACR2025! View the poster here: contexttherapeutics.com/ct95 #Immunotherapy #Biotech $CNTX

🚨 We’re excited to welcome Jennifer Dashnau, PhD, MBA as SVP of Technical Operations at Context Therapeutics! Welcome to the team, Jennifer! 👏 #Biotech #Leadership #Immunotherapy #TCellEngagers #ContextTherapeutics #Oncology #WomenInSTEM

🚨 Context Therapeutics $CNTX Q1 2025 Highlights: ✅ CTIM-76 & CT-95 in Phase 1 trials ✅ $89.4M cash and cash equivalents as of March 31, 2025 ✅ Expected cash runway into 2027 #Biotech #Immunotherapy #CancerResearch #TCellEngagers Read more here:ir.contexttherapeutics.com/news-releases/…

We’re excited to welcome Dr. Karen Chagin as Chief Medical Officer at $CNTX, effective June 9, 2025! With 10+ years leading T cell therapy development at Adaptimmune and Tmunity, she brings deep clinical expertise at a key time for Context. Read more: tinyurl.com/5c78te9f

$CNTX announces CTIM-76 Trial in Progress poster at #ASCO25 ✅Dosing Cohort 3 of Phase 1 trial ✅ CLDN6 x CD3 TCE for ovarian, endometrial & testicular cancers ✅Initial data expected 1H 2026 📍Poster: June 2, Hall A, 1:30 PM CDT 🔗 contexttherapeutics.com/ctim76 #Biotech

Context Therapeutics $CNTX Q2 2025 Highlights: ✅ CTIM-76 & CT-95 Phase 1 dose-escalation trials ongoing ✅ $83.5M cash and cash equivalents as of June 30, 2025 ✅ Expected cash runway into 2027 Read more here: ir.contexttherapeutics.com/news-and-event… #Biotech #Immunotherapy #CancerRes #TCE

Our CEO, Martin Lehr, will participate in a fireside chat at the Cantor Fitzgerald Global Healthcare Conference tomorrow, September 3rd. #cantor, #TCE, $CNTX